MX2023010750A - Nuevos usos de derivados de piperidinil-indol. - Google Patents

Nuevos usos de derivados de piperidinil-indol.

Info

Publication number
MX2023010750A
MX2023010750A MX2023010750A MX2023010750A MX2023010750A MX 2023010750 A MX2023010750 A MX 2023010750A MX 2023010750 A MX2023010750 A MX 2023010750A MX 2023010750 A MX2023010750 A MX 2023010750A MX 2023010750 A MX2023010750 A MX 2023010750A
Authority
MX
Mexico
Prior art keywords
piperidinyl
indole derivatives
novel uses
treatment
patients suffering
Prior art date
Application number
MX2023010750A
Other languages
English (en)
Inventor
Jörg Eder
Richard Alexander Harrison
Boerje Haraldsson
Anna Svenja Schubart
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2023010750A publication Critical patent/MX2023010750A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere al uso novedoso de ciertos derivados de piperidinil-indol en el tratamiento de pacientes que padecen enfermedades o trastornos renales, y en particular, para el tratamiento de pacientes que padecen C3G (glomerulopatía C3) e IgAN (nefropatía por IgA).
MX2023010750A 2017-08-31 2020-02-26 Nuevos usos de derivados de piperidinil-indol. MX2023010750A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17188870 2017-08-31

Publications (1)

Publication Number Publication Date
MX2023010750A true MX2023010750A (es) 2023-09-20

Family

ID=59745840

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020002185A MX2020002185A (es) 2017-08-31 2018-08-30 Nuevos usos de derivados de piperidinil-indol.
MX2023010750A MX2023010750A (es) 2017-08-31 2020-02-26 Nuevos usos de derivados de piperidinil-indol.
MX2023010751A MX2023010751A (es) 2017-08-31 2020-02-26 Nuevos usos de derivados de piperidinil-indol.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020002185A MX2020002185A (es) 2017-08-31 2018-08-30 Nuevos usos de derivados de piperidinil-indol.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023010751A MX2023010751A (es) 2017-08-31 2020-02-26 Nuevos usos de derivados de piperidinil-indol.

Country Status (12)

Country Link
US (2) US11723901B2 (es)
EP (2) EP4393545A3 (es)
JP (3) JP6754919B1 (es)
KR (3) KR102682887B1 (es)
CN (5) CN117398384A (es)
AU (1) AU2018326768B2 (es)
BR (1) BR112020003737A2 (es)
CA (1) CA3073346A1 (es)
CL (1) CL2020000483A1 (es)
IL (1) IL272888B2 (es)
MX (3) MX2020002185A (es)
WO (1) WO2019043609A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021125313A1 (ja) * 2019-12-19 2021-06-24 大鵬薬品工業株式会社 縮合ピリミジン化合物を有効成分とする治療剤
CN115667240A (zh) 2020-05-18 2023-01-31 诺华股份有限公司 Lnp023的结晶形式
US20230331710A1 (en) * 2020-08-07 2023-10-19 Shanghai Meiyue Biotech Development Co. Ltd Heterocyclic compound, preparation method and use thereof
KR20230049115A (ko) 2020-08-07 2023-04-12 상하이 메이유에 바이오테크 디벨롭먼트 컴퍼니 리미티드 보체 인자 b 억제제 및 이의 약학적 조성물, 제조 방법 및 용도
AU2021414185A1 (en) * 2020-12-30 2023-08-10 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Nitrogen-containing bridged heterocyclic compound, preparation method therefor, and medical use thereof
CN117479937A (zh) * 2021-05-07 2024-01-30 诺华股份有限公司 用于治疗非典型溶血性尿毒综合征的伊普可泮
AU2022329230A1 (en) * 2021-08-18 2024-03-21 Xizang Haisco Pharmaceutical Co., Ltd. Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicine
MX2024004921A (es) * 2021-10-27 2024-06-19 Hansoh Bio Llc Derivados de piperidinilindol, metodos de preparacion y usos medicinales de estos.
WO2023139534A1 (en) * 2022-01-24 2023-07-27 Novartis Ag Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof
WO2023143293A1 (zh) * 2022-01-26 2023-08-03 上海美悦生物科技发展有限公司 补体因子b抑制剂的盐型、晶型及其制备方法和应用
WO2023237041A1 (zh) * 2022-06-10 2023-12-14 正大天晴药业集团股份有限公司 双环取代的芳香羧酸酯类化合物
WO2023246677A1 (zh) * 2022-06-20 2023-12-28 深圳信立泰药业股份有限公司 一种吲哚-苯基哌啶化合物及其制备方法与应用
WO2024002353A1 (zh) * 2022-06-30 2024-01-04 江苏恒瑞医药股份有限公司 一种含氮桥杂环衍生物的可药用盐、晶型及其制备方法
WO2024051849A1 (en) * 2022-09-10 2024-03-14 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. 2-substituted piperidine derivatives, preparation methods and medicinal uses thereof
CN118026998A (zh) * 2022-11-11 2024-05-14 上海医药工业研究院有限公司 哌啶取代的苯甲酸类化合物、其药物组合物和应用
WO2024141011A1 (zh) * 2022-12-31 2024-07-04 深圳晶泰科技有限公司 补体因子b抑制剂及其药物组合物和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8192742B2 (en) * 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
EP2867227B1 (en) * 2012-06-28 2018-11-21 Novartis AG Complement pathway modulators and uses thereof
JO3425B1 (ar) * 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
EP3394089B1 (en) * 2015-12-23 2021-07-28 eleva GmbH Polypeptides for inhibiting complement activation

Also Published As

Publication number Publication date
MX2020002185A (es) 2020-07-14
BR112020003737A2 (pt) 2020-09-01
EP4393545A2 (en) 2024-07-03
JP2021181471A (ja) 2021-11-25
RU2020111788A3 (es) 2021-12-28
AU2018326768B2 (en) 2021-07-29
US11723901B2 (en) 2023-08-15
CN117338781A (zh) 2024-01-05
JP2020529466A (ja) 2020-10-08
EP4393545A3 (en) 2024-09-25
CN111032042A (zh) 2020-04-17
MX2023010751A (es) 2023-09-20
RU2020111788A (ru) 2021-09-30
WO2019043609A1 (en) 2019-03-07
IL272888B2 (en) 2024-01-01
CN117338783A (zh) 2024-01-05
IL272888B1 (en) 2023-09-01
KR20230024432A (ko) 2023-02-20
JP6754919B1 (ja) 2020-09-16
JP2020193222A (ja) 2020-12-03
JP7297016B2 (ja) 2023-06-23
KR20240111007A (ko) 2024-07-16
KR20200047540A (ko) 2020-05-07
AU2018326768A1 (en) 2020-02-06
CN117398384A (zh) 2024-01-16
IL272888A (en) 2020-04-30
KR102497487B1 (ko) 2023-02-08
CL2020000483A1 (es) 2020-09-04
EP3675854A1 (en) 2020-07-08
JP6929425B2 (ja) 2021-09-01
US20220152011A1 (en) 2022-05-19
CN117338782A (zh) 2024-01-05
US20200338059A1 (en) 2020-10-29
CA3073346A1 (en) 2019-03-07
KR102682887B1 (ko) 2024-07-08

Similar Documents

Publication Publication Date Title
MX2023010751A (es) Nuevos usos de derivados de piperidinil-indol.
AU2019268063A1 (en) Compositions for modulating sod-1 expression
MX2018000542A (es) Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias.
PH12018500057A1 (en) Substituted oxopyridine derivatives
MX2021007268A (es) Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.
MX2020011749A (es) Composiciones y metodos para modular la expresion de pkk.
PH12015501806B1 (en) Novel benzopyran kinase modulators
NZ737399A (en) Ccr2 modulators
HK1146485A1 (es)
EP3598980A3 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
TW201613636A (en) Methods of treating Alzheimer's Disease
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
MX2018014718A (es) Compuestos y su uso para reducir los niveles de ácido úrico.
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
EP2563794A4 (en) INHIBITORS OF TYROSINE KINASE PROTEIN ACTIVITY AND THEIR APPLICATIONS TO THE TREATMENT OF OPHTHALMIC DISORDERS
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
PH12019500535A1 (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
PH12019502315A1 (en) Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
WO2015155680A3 (en) Pyrazole derivatives as dihydroorotate dehydrogenase (dhodh) inhibitors
MX2017007676A (es) Nuevos compuestos.
PH12017501872A1 (en) Methods of treating diseases
MX2019012153A (es) N-ariletil-2-arilquinolina -4-carboxamidas sustituidas y su uso.
NZ747201A (en) (+)-azasetron for use in the treatment of ear disorders
MX2016016371A (es) Nuevos compuestos.